Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus—A case series and literature review

Reem A Bahmaid¹, Shoroq Ammar², Sarah Al-Subaie², Mohammed A Soofi¹, Hassan Mhish¹ and Madonna Ali Yahia²

Abstract

Background: Left ventricular thrombus (LVT) is a frequent complication of acute myocardial infarction and a risk factor for thromboembolic complications. Warfarin has been frequently used, but has some disadvantages that limit its use. Direct oral anticoagulants, in particular Dabigatran and Rivaroxaban have been proved to be effective in preventing thromboembolism among patients with non-valvular atrial fibrillation. However, no randomized clinical trials testing the efficacy and safety of these agents in patients with existing left ventricular thrombus. Furthermore, direct oral anticoagulants are still not approved by the Food and Drug Administration in the management of left ventricular thrombus.

Method: This study was a retrospective cohort assessing the efficacy of direct oral anticoagulants (Dabigatran or Rivaroxaban) on the resolution of left ventricular thrombus in patients taking either of these drugs during the study period from December, 2011 to December, 2016 at King Fahad Medical City. All patients' records were reviewed and all patients who were diagnosed with left ventricular thrombus were included. Patients without available echocardiogram records were excluded. The study was approved by the institutional review board of King Fahad medical city, Riyadh Saudi Arabia.

Result: During the defined study period we found that 413 and 1218 patients were taking Dabigatran and Rivaroxaban, respectively. After filtering them based on the specialty of the prescriber, we ended up with 299 patients who have been started on Dabigatran and 448 patients who have been started on Rivaroxaban by cardiologists. Moreover, after reviewing echocardiogram reports for all of them (747 patients), we found that 11 patients were diagnosed to have left ventricular thrombus. Among those 11 patients, seven of them were treated with direct oral anticoagulants from the beginning and the remaining four patients were shifted from Warfarin to direct oral anticoagulants. All of them (7 patients) showed left ventricular thrombus resolution on follow-up echocardiogram.

Conclusion: Use of direct oral anticoagulants showed promising results in the resolution of left ventricular thrombus in patients diagnosed with left ventricular thrombus. Further studies at multiple health care centers are needed to further evaluate the efficacy and safety of direct oral anticoagulants as compared to traditional treatment in patients with left ventricular thrombus.

Keywords

Left ventricular thrombus, direct oral anticoagulants, acute myocardial infarction

Received 2 January 2019; Revised received 17 February 2019; accepted 28 February 2019

Background

Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction (AMI).¹ The risk of LVT formation increases with infarction size; larger infarction implies a larger area of tissue injury resulting...
in stagnation of ventricular blood. The most common type of LVT is mural thrombus. Echocardiography (ECHO) is the main diagnostic tool used for LVT, which appears as a visible mass in the left ventricle while computed tomography and magnetic resonance imaging are effective, but less commonly used due to their cost and risks.

Mobility and protrusion of the thrombus are two characteristics associated with increased embolic potential. The European Heart Journal guidelines published in 2012 stated that patients with mural thrombi require oral anticoagulant (OAC) with vitamin-K antagonist (VKA) therapy for up to six months, while the American College of Cardiology/American Heart Association (ACC/AHA) 2013 guidelines limited the use of VKA therapy to three months in patients who have LVT or are at risk for LVT, such as patients with antero-apical akinesis or dyskinesis. There is still a controversy regarding stopping treatment after resolution of thrombus or continuing treatment.

Warfarin is an OAC used as standard therapy for LVT. It has debatable safety and many clinical limitations, including multiple foods and drug interactions, a slow onset of action and narrow therapeutic range for preventing thrombosis and minimizing hemorrhagic complications. These disadvantages increase the need to investigate safer, more practical, and effective alternatives to Warfarin. Although the role of direct oral anticoagulants (DOACs) for the treatment of LVT is not yet established, however DOACs (Dabigatran and Rivaroxaban) have proved their non-inferiority to Warfarin in the prevention of thrombosis and minimizing hemorrhagic complications. These disadvantages increase the need to investigate safer, more practical, and effective alternatives to Warfarin. Although no randomized clinical trial was testing the efficacy and safety of these agents among patients with LVT exists, and DOACs are not approved by the Food and Drug Administration (FDA) in the management of LVT however, there is an increasing body of evidence pointing towards effectiveness of these agents on dissolving LVT.

Methods

This study was a retrospective cohort assessing the efficacy of DOACs (Dabigatran or Rivaroxaban) on the resolution of LVT in patients taking either of these drugs during the study period from December, 2011 to December, 2016 at King Fahad Medical City. Data were collected from the hospital medical records for patients taking either of the two drugs. All records were reviewed, and all patients who were Diagnosed or Rivaroxaban with LVT were included. Patients without available echocardiogram (ECHO) records were excluded. Follow-up was done for all cases until June, 2017. The study was approved by the institutional review board (IRB) of King Fahad medical city, Riyadh Saudi Arabia.

Results

During the defined study period we found that 413 and 1218 patients were taking Dabigatran and Rivaroxaban, respectively. After filtering them based on the specialty of the prescriber, we ended up with 299 patients started on Dabigatran and 448 patients started on Rivaroxaban that prescribed by cardiologists. Moreover, after reviewing ECHO reports for all of them (747 patients), we found that 11 patients were diagnosed to have LVT. Among those 11 patients, seven of them were treated with DOACs from the beginning and the remaining four patients were shifted from Warfarin to DOACs. Those four patients who were treated first with Warfarin were excluded, and we did further data collection for the seven patients who started on DOACs, all of them are male, with mean ages 49 ± 18.3 years; one patient has acute coronary syndrome that required cardiac catheterization and stent implementation, this patient was kept on low dose aspirin plus clopidogrel, another patient has atrial fibrillation (AF) in addition to the LVT and six out of seven patients have heart failure with reducing ejection fractions (Figure 1).

Interestingly, follow-up ECHO for all of them showed LVT resolution, but we found variation in documented time for follow-up ECHO without clear reasons that have a clear impact on the anticoagulant duration, means ECHO follow-up was 10.3 month and median 4 month. Tables 1, 2, and 3 summarized all cases.

Discussion

This study shows successful resolution of LVT in all patients treated with DOACs, despite the variation in documented time for follow-up ECHO without clear reasons that have a clear impact on the anticoagulant duration, means ECHO follow-up was 10.3 month and median 4 month. Tables 1, 2, and 3 summarized all cases.
Rivaroxaban, and five patients were on Dabigatran. Patients were managed with anticoagulation therapy for a period ranging from seven days to four months. None of the patients exhibited any bleeding incident due to use of DOACs. Moreover, our result shows the successful result of LV thrombus resolution which was previously achieved with Warfarin therapy only.

Nevertheless, our results support the AHA/American Stroke Association guidelines on stroke prevention, 2014 that introduced a new recommendation advising that Low Molecular Weight Heparin, Dabigatran, Rivaroxaban, or Apixaban may be considered as an alternative to VKAs for post-MI LVT for patients not tolerating VKAs due to non-hemorrhagic adverse events.

Figure 1. Patients distribution.

Table 1. Summary of baseline patients’ cases.

| Case number | Demographics | DOAC used/mg | Calculated CrCl (ml/min) | EF% | Total duration of anticoagulant therapy duration (months) |
|-------------|--------------|--------------|--------------------------|-----|--------------------------------------------------------|
|             | Age (year)   | Weight (kg)  | Height (cm)              |     |                                                        |
| 1           | 21           | 58           | 164                      | R / 20 mg daily | 105.3 | 35 | 28 |
| 2           | 74           | 55           | 175                      | R / 15 mg daily | 54    | 60 | 3  |
| 3           | 51           | 83           | 170                      | R / 20 mg daily | 115   | 15 | 4  |
| 4           | 50           | 90           | 174                      | R / 20 mg daily | 98.6  | 25 | 23 |
| 5           | 45           | 76           | 191                      | D / 100 mg twice | 58    | 50 | 2  |
| 6           | 68           | 75           | 170                      | R / 20 mg daily | 66.3  | 35 | 24 |
| 7           | 34           | 94           | 175                      | R / 15 mg daily | 142   | 20 | 4  |

R: Rivaroxaban; D: Dabigatran; DOAC: direct oral anticoagulant; EF: ejection fraction

Table 2. Summary of patients’ lab.

|                      | Frequency | Mean ± SD | Median (min, max) |
|----------------------|-----------|-----------|-------------------|
| Hb (baseline)        | 6         | 15.1 ± 1.4| 15.2 (13.1, 16.6) |
| Hb (follow-up)       | 6         | 14.8 ± 1.3| 15.2 (12.9, 16)   |
| CrCl (baseline)      | 6         | 95.5 ± 34 | 102 (54, 142)     |
| CrCl (follow-up)     | 7         | 93.3 ± 33.2| 95.3 (56, 142)    |
| INR (baseline)       | 7         | 1.3 ± 0.3 | 1.1 (1, 1.9)      |
| INR (follow-up)      | 6         | 1.2 ± 0.2 | 1.1 (1, 1.5)      |
| aPTT (baseline)      | 6         | 35.5 ± 5.5| 35.8 (27.9, 44.5) |
| aPTT (follow-up)     | 6         | 44.8 ± 13.3| 39.1 (32.6, 68.9) |
| ALT (baseline)       | 6         | 44 ± 46.6 | 27 (8, 136)       |
| ALT (follow-up)      | 7         | 20.1 ± 8.1| 23 (6, 30)        |

ALT: alanine aminotransferase; aPTT: activated partial thromboplastin time; BMI: body mass index; INR: international normalized ratio

Rivaroxaban, and five patients were on Dabigatran. Patients were managed with anticoagulation therapy for a period ranging from seven days to four months. None of the patients exhibited any bleeding incident due to use of DOACs. Moreover, our result shows the successful result of LV thrombus resolution which was previously achieved with Warfarin therapy only.

Nevertheless, our results support the AHA/American Stroke Association guidelines on stroke prevention, 2014 that introduced a new recommendation advising that Low Molecular Weight Heparin, Dabigatran, Rivaroxaban, or Apixaban may be considered as an alternative to VKAs for post-MI LVT for patients not tolerating VKAs due to non-hemorrhagic adverse events.
Use of direct oral anticoagulants showed promising results in the resolution of LVT in patients diagnosed with LVT. Further studies at multiple health care centers are needed to further evaluate the efficacy and safety of DOACs as compared to traditional treatment in patients with LVT.

Summary of current cases

Case I: A 21-year-old male with a history of labile international normalized ratio (INR) was admitted to the hospital in January 2015 with the diagnosis of LVT. Upon admission patient’s baseline laboratory investigations were normal with normal sinus rhythm on ECG. On the second day of admission, transthoracic echocardiography (TTE) was performed which revealed an apical thrombus with severe global LV systolic dysfunction, moderate to severe tricuspid regurgitation and severe pulmonary hypertension. The patient was started on warfarin to achieve a target INR of 2–3 and discharged in a stable condition. At five months follow-up, TTE showed persistent LVT, and warfarin was replaced by rivaroxaban 20 mg daily for a year at the end of which the follow-up transesophageal echocardiography (TEE) showed complete resolution of LVT.

Case II: A 74-year-old male with a history of hypertension was admitted in August 2015 as a case of acute coronary syndrome. All pertinent baseline laboratory investigations were normal. ECG on admission showed: Q-waves in V1 and V2, deep T-wave inversion in V2, V3, V4, T-wave inversion in inferior leads V5 and V6. Furthermore, TTE revealed that the left ventricle was mildly dilated. Left ventricular ejection fraction was 35%, and there was a moderate size apical thrombus, and an abnormality in regional wall motion and mild mitral regurgitation. Consequently, coronary cardiography was done with percutaneous coronary intervention (PCI) and the patient was started on acute coronary syndrome treatment regimen including aspirin 81 mg and clopidogrel 75 mg daily, and rivaroxaban 15 mg daily for three months for management of LVT. On November 2015, TTE showed the resolution of thrombus.

Case III: A 51-year-old male was diagnosed with LVT in September 2015, based on the TTE result which showed normal-sized left ventricle, mildly reduced systolic function, 50% ejection fraction with dyskinetic apex and apical thrombus. The right ventricle was normal in size and function, and there were no hemodynamically significant valvular disease and no pericardial effusion. All pertinent baseline laboratory investigations were normal, and ECG showed normal sinus rhythm. The patient was started on rivaroxaban 20 mg daily and the follow-up TTE at three months showed apical dyskinesia with spontaneous echo-contrast but no obvious thrombus as before.

Case IV: A 50-year-old male with a history of ischemic heart disease, hypertension, and diabetes mellitus was diagnosed with LVT in December 2014. TEE showed moderate size apical thrombus, moderately dilated left ventricle, ejection fraction of 25–30%, and regional wall motion abnormalities. All pertinent baseline laboratory investigations were normal. ECG showed normal sinus rhythm and possible left atrial enlargement. He was started on rivaroxaban 20 mg daily in addition to ischemic heart disease regimen. After two years, TEE showed resolution of the LV apical thrombus.

Case V: A 45-year-old male with a history of AF was diagnosed with LVT in June 2015. TTE done at that time showed severely dilated left ventricle, large apical thrombus, left ventricular ejection fraction of less than 20%, severe global hypokinesis of the left ventricle, moderately dilated right ventricle, moderate to severely reduced right ventricular systolic function, moderate mitral regurgitation, and moderate tricuspid regurgitation. All other baseline laboratory investigations were normal. ECG showed multiple premature ventricular contractions with underlying sinus rhythm. Dabigatran 110 mg twice daily (BID) was started. The follow-up TTE done at two months showed resolution of LVT.

### Table 3. Medical History of Patients.

| Medical History                  | n (%) |
|----------------------------------|-------|
| Child-Pug (baseline)             |       |
| Class A                          | 4 (57.1) |
| Class B                          | 3 (42.9) |
| Child-Pug (follow-up)            |       |
| Class A                          | 5 (71.4) |
| Class B                          | 2 (28.6) |
| Acute coronary syndrome          | 1 (14.3) |
| AF                               | 1 (14.3) |
| Hypertension                     | 3 (42.9) |
| EF                               | 1 (14.3) |
| Dyslipidemia                     | 1 (14.3) |
| CVA infarction                   | 1 (14.3) |
| Diabetes                         | 2 (28.6) |
| Alcohol                          | 1 (14.3) |
| DOAC used                        |       |
| D                                | 1 (14.3) |
| R                                | 6 (85.7) |
| LVT resolution                   | 7 (100.0) |

AF: atrial fibrillation; CVA: cerebrovascular accident; DOAC: direct oral anticoagulant; EF: ejection fraction; LVT: left ventricular thrombus.
Case VI: A 68-year-old male was diagnosed with LVT in April 2014, and TTE showed a large apical thrombus, moderately reduced left the ventricular systolic function, ejection fraction of 35–45%, regional wall motion abnormalities, and a large apical aneurysm. His laboratory investigations were normal, and ECG showed sinus bradycardia. The patient was started on rivaroxaban 15 mg daily for two years. Follow-up TTE done at two years follow-up showed no apical LV thrombus.

Case VII: A 34-year-old male with a history of hypertension, heart failure with reduced ejection fraction, dyslipidemia, ischemic heart disease, diabetes mellitus, and cerebrovascular accident infarction was diagnosed with LVT in September 2016. TTE showed a moderate size apical thrombus, left ventricular ejection fraction of 40–45%, and hypokinetic left ventricular apex. All baseline laboratory investigations and ECG were normal. Rivaroxaban 15 mg was given daily for three months. In the next follow-up, TTE showed no thrombus in LV apex.

Highlights
- Using DOAC for dissolving LVT has a great advantage over using warfarin which requires frequent laboratory monitoring at least every six weeks with a steady range.
- DOAC are not being studied in LVT resolution; therefore, this report may shed light on this topic.
- There is a need for conducting randomized clinical trials testing the safety and efficacy of DOAC in resolving LVT.

Contributorship
Reem: reviewing data and proposal, Writing manuscript, edit manuscript, submitted to the journal
Shroq and MAha: writing proposal, collecting data and clean data
ASoofi: reviewing study proposal
Hassan: reviewing study proposal
Madona: reviewing proposal and manuscript

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
This study was approved by KFMC IRB office with IRB no. 17–178.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Guarantor
Reem Bahmaid

ORCID iD
Reem A Bahmaid http://orcid.org/0000-0001-9944-4725

References
1. Delewi R, Zijlstra F and Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart 2012; 98: 1743–1749.
2. Haugland JM, Asinger RW, Mikell FL, et al. Embolic potential of left ventricular thrombi detected by two-dimensional echocardiography. Circulation 1984; 70: 588–598.
3. Nakasuka K, Ito S, Noda T, et al. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep Med 2014; 2014: 814524.
4. Cross P and Stewart R. Left ventricular mural thrombus treated with dabigatran. J Case Rep Stud 2014; 2: 402.
5. Chung K, Paek YM, Lee HJ, et al. Dabigatran effect on left ventricular thrombus in a patient with acute ischemic stroke. J Stroke 2015; 17: 366–368.
6. Yanikoglu A, Altintas MS and Ekinouz I. Dissolution of an apical thrombus by apixaban in a patient with old anteroseptal myocardial infarction. Anatol J Cardiol 2015; 15: 671–672.
7. Kolekar S, Munjewar C, Sharma S, et al. Dabigatran for left ventricular thrombus. Indian Heart J 2015; 67: 495–496.
8. Ohashi N, Okada T, Uchida M, et al. Effects of dabigatran on the resolution of left ventricular thrombus after acute myocardial infarction. Intern Med 2015; 54: 1761–1763.
9. Assadullah Azizi NB, Puricel S and Cook S. Rivaroxaban dissolves post infarction left ventricular thrombus. Cardiovasc Med 2016; 19: 25–27.
10. Seecheran R, Seecheran V, Persad S, et al. Rivaroxaban as an antithrombotic agent in a patient with ST-segment elevation myocardial infarction and left ventricular thrombus. J Invest Med High Impact Case Rep 2017; 5: 232470961769799.

Appendix I

Published case reports

Case I: In 2013, Bunji Kaku reported a case presented with left ventricular thrombus with a history of midventricular obstructive hypertrophic cardiomyopathy in Japan. The patient was treated with dabigatran 150 mg BID. Weekly echocardiography was done and showed a gradual decrease in thrombus size. After three weeks, echocardiogram showed complete resolution of thrombus, but the patient was continued on dabigatran.
| Author               | Year | Country    | Age | Gender | Co morbidities                                                                 | Other medications                                      | TSOAC used        | Duration of anticoagulant | LVT resolution | Anticoagulation continuation | Complications |
|----------------------|------|------------|-----|--------|--------------------------------------------------------------------------------|--------------------------------------------------------|-------------------|--------------------------|----------------|--------------------------------|----------------|
| Kaku                 | 2013 | Japan      | 59  | Male   | Mid-ventricular obstructive hypertrophic cardiomyopathy                         | None                                                   | Dabigatran 150 mg BID | 21 days                  | Thrombus resolved | Dabigatran resumed            | None           |
| Nakasuka et al.      | 2014 | Japan      | 42  | Male   | Heart failure (NYHA class III), atrial fibrillation, tachycardia and pitting edema on the lower extremities, IBS | Heparin and warfarin for 1 day                         | Rivaroxaban 15 mg once daily | 7 days                    | Thrombus resolved | Unknown                                      | None           |
| Cross and Stewart    | 2014 | New Zealand | 65  | Female | STEMI, history of SAH                                                           | None                                                   | Dabigatran 150 mg BID | 30 days                  | Thrombus resolved | Dabigatran stopped                          | None           |
| Chung et al.         | 2015 | Korea      | 57  | Male   | Acute stent insertion in the proximal left anterior descending artery & atrial fibrillation | Alteplase (0.9 mg/kg) IV                               | Apixaban 5 mg BID    | 30 days                  | Thrombus resolved | Unknown                                      | None           |
| Yanikoglu et al.     | 2015 | Turkey     | 55  | Male   | Anterior MI since 6 years. EF = 45%                                              | Previous warfarin (suffered from GI bleed due to noncompliance, INR = 7) | Dabigatran 110 mg BID | 4 months                  | Thrombus resolved | Unknown                                      | None           |
| Kolekar et al.       | 2015 | India      | 61  | Male   | Congestive heart failure, stroke, scar epilepsy, atrial fibrillation, diabetes, hypertension, and ventricular tachycardia | None                                                   | Dabigatran 110 mg BID for 4 months | 18 days                  | Thrombus resolved | Dabigatran 110 mg BID for 6 months | None           |
| Ohashi et al.        | 2015 | Japan      | 78  | Male   | Hypertension, paroxysmal atrial fibrillation and stenosis post PCI in the proximal left anterior descending artery 7 years ago | None                                                   | Dabigatran 110 mg BID | 18 days                  | Thrombus resolved | Dabigatran 110 mg BID for 6 months | None           |
| Assadullah Azizi et al | 2016 | Switzerland | 54  | Male   | STEMI                                                                              | DAPT                                                   | Rivaroxaban 20 mg everyday | 30 days                  | Thrombus resolved | Rivaroxaban was further continued for 3 months | Persistence of apical dyskinesia |

BID: twice daily; DAPT: dual antiplatelet therapy; EF: ejection fraction; GI: gastrointestinal; IBS: irritable bowel syndrome; LVT: left ventricular thrombus; MI: myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; SAH: subarachnoid hemorrhage; STEMI: ST-elevation myocardial infarction; TSOACs: target-specific oral anticoagulants.
**Case II:** In 2014, Kosuke Nakasuka reported a case of a patient from Japan presenting with a left ventricular thrombus with a history of heart failure (New York Heart Association (NYHA) class III), AF, tachycardia, and pitting edema on lower extremities. He was started on warfarin and heparin as bridge therapy for one day and later replaced with rivaroxaban 15 mg once daily. The ball in LV disappeared without any signs and symptoms of cardiogenic embolism after seven days from introducing rivaroxaban. Repeated echo showed resolution of thrombus.

**Case III:** In 2014, Cross from New Zealand reported a case of a female patient with a history of subarachnoid hemorrhage (SAH) in left precentral sulcus due to head trauma. The patient presented with palpitations, sinus rhythm, and 1–2 mm ST elevation. She was not managed with anticoagulants or anti-platelet drugs for the presence of recent SAH and stable clinical status, and coronary angiography was postponed. On day 7, follow-up computed tomography (CT) head scan showed resolution of the SAH, and coronary angiography identified spontaneous dissection of the mid and distal left anterior descending coronary artery, with good blood flow to the distal vessel. Left ventriculography demonstrated antero-apical akinesia and an apical mural thrombus. The mural thrombus was confirmed by echocardiogram, and the patient was started on dabigatran 150 mg BID. At the day 30, follow-up ECHO showed recovery of left ventricular function and no mural thrombus.

**Case IV:** In 2015, Kyuyoon Chung reported a case from South Korea with a documented left ventricular thrombus with a history of acute stent insertion in the proximal left anterior descending artery and AF. Upon admission, the patient was started on IV alteplase therapy (0.9 mg/kg). The patient exhibited improvement after 24 h. Echocardiogram showed left ventricular apical thrombus associated with apical inferior wall akinesia. On day 2, the patient was started on dabigatran 110 mg BID. After seven days of using dabigatran, follow-up echocardiogram showed the disappearance of LVT without any problems. Subsequently, the patient has introduced with dabigatran 150 mg BID.

**Case V:** In 2015, a case report was published by Atakan Yanıkoglu in Turkey, which summarized a case of a non-compliant patient with a history of anterior MI for six years with ejection fraction of 45%. Echocardiogram revealed a mobile apical thrombus. The patient was started on apixaban 5 mg BID. Later, ECHO performed after two weeks revealed a suspicious apical thrombus which resolved after one month.

**Case VI:** In 2015, a case report by Satishkumar Kolekar in India described a patient with mobile mass in the left ventricle with a history of congestive heart failure, stroke, scar epilepsy, AF, diabetes, hypertension, and ventricular tachycardia. The patient was treated with dabigatran 110 mg BID for four months. TEE performed after four months revealed the complete resolution of thrombus.

**Case VII:** In 2015, Norihiko Ohashi in Japan reported a case with left ventricular thrombus and a history of hypertension, paroxysmal AF and stenosis post PCI in the proximal left anterior descending artery seven years ago. Follow-up ECHO performed after 10 days post-admission showed immobile thrombi in the apex of the left ventricle. The patient was started on dabigatran 110 mg BID. ECHO repeated on day seven after receiving dabigatran showed a significant reduction in the size of thrombus. Later ECHO performed on day 18 showed complete thrombus resolution. The patient continued to receive dabigatran 110 mg BID for six months after discharge. The patient did not develop any serious bleeding complications and had remained free of LVT recurrence.

**Case VIII:** In 2016, Assadullah Azizi reported a patient presented with left ventricular thrombus and a history of ST-elevation myocardial infarction (STEMI) in Switzerland. The patient was treated with dual anti-platelet therapy (DAPT) and rivaroxaban 20 mg once daily. Follow-up TEE done after one month of rivaroxaban therapy showed complete resolution of thrombus despite the persistence of the apical dyskinesia; the patient was continued on rivaroxaban for three months.